Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Processa Pharmaceuticals, Inc.PCSA · Entity 8210 | Director | July 26, 2026 | July 29, 2026 |
| RBB BancorpRBB · Entity 5572 | Director | May 21, 2026 | May 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Processa Pharmaceuticals, Inc.
Report date July 26, 2026 · Filed July 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 38,749 |
Reported balance
After 2026-07-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-26 · Grant · Acquired 33,500 · Balance 38,749 F1: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death. F3: Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025. |
| Common StockSEC Table I · non-derivative | Direct | 2,391 |
Reported balance
Holding disclosure · report date 2026-07-26 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 2,391 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.96 | Direct | 12,000 |
Reported balance
Holding disclosure · report date 2026-07-26 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 12,000 F2: Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years. F3: Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death.
F2: Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years.
F3: Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025.
RBB Bancorp
Report date May 21, 2026 · Filed May 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, No Par ValueSEC Table I · non-derivative | Direct | 8,267 |
Ending reported balance
After 2026-05-21 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-21 · Exercise / conversion · Acquired 700 · Balance 6,421 Row 2 · 2026-05-21 · Exercise / conversion · Acquired 1,846 · Balance 8,267 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-21 · Exercise / conversion · Disposed 700 · Balance 0 F1: Restricted stock units convert into common stock on a one-for-one basis. F2: On May 21, 2025, the reporting person was granted 3,521 restricted stock units: 2,821 immediately vested and 700 vested on the one year anniversary of the grant date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 2,546 |
Reported balance
After 2026-05-21 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-21 · Grant · Acquired 2,546 · Balance 2,546 F1: Restricted stock units convert into common stock on a one-for-one basis. F3: On May 21, 2026, the reporting person was granted 2,546 restricted stock units: 1,846 vested immediately and 700 will vest on the one year anniversary of the grant date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 700 |
Reported balance
After 2026-05-21 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-05-21 · Exercise / conversion · Disposed 1,846 · Balance 700 F1: Restricted stock units convert into common stock on a one-for-one basis. F3: On May 21, 2026, the reporting person was granted 2,546 restricted stock units: 1,846 vested immediately and 700 will vest on the one year anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units convert into common stock on a one-for-one basis.
F2: On May 21, 2025, the reporting person was granted 3,521 restricted stock units: 2,821 immediately vested and 700 vested on the one year anniversary of the grant date.
F3: On May 21, 2026, the reporting person was granted 2,546 restricted stock units: 1,846 vested immediately and 700 will vest on the one year anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 26, 2026 Filed Jul 29, 2026 00:27 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 33,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-26-001556 · form4.xml · derivative · entry 2 Pannu Geraldine · CIK 0001817209 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,749 Underlying: Common Stock · 33,500 shares Expires not disclosed F1 · shares: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death. F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death. F3 · balance_after: Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025. Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 20:48 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionRestricted Stock · Derivative | 203 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-26-001470 · form4.xml · derivative · entry 2 Pannu Geraldine · CIK 0001817209 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,249 Underlying: Common Stock · 203 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Distribution of time-based service award. F1 · derivative.expiration_date: Distribution of time-based service award. Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 20:48 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionCommon Stock | 203 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000897069-26-001470 · form4.xml · nonDerivative · entry 1 Pannu Geraldine · CIK 0001817209 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,391 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Distribution of time-based service award. Read SEC document |
| May 21, 2026 Filed May 27, 2026 00:12 UTC | RBB Bancorp RBB · Entity 5572 | Exercise / conversionRestricted Stock Units · Derivative | 1,846 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-018419 · rdgdoc.xml · derivative · entry 5 Pannu Geraldine · CIK 0001817209 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 700 Underlying: Common Stock · 1,846 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On May 21, 2026, the reporting person was granted 2,546 restricted stock units: 1,846 vested immediately and 700 will vest on the one year anniversary of the grant date. F3 · derivative.expiration_date: On May 21, 2026, the reporting person was granted 2,546 restricted stock units: 1,846 vested immediately and 700 will vest on the one year anniversary of the grant date. Read SEC document |
| May 21, 2026 Filed May 27, 2026 00:12 UTC | RBB Bancorp RBB · Entity 5572 | GrantRestricted Stock Units · Derivative | 2,546 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-018419 · rdgdoc.xml · derivative · entry 4 Pannu Geraldine · CIK 0001817209 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,546 Underlying: Common Stock · 2,546 shares Expires not disclosed F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On May 21, 2026, the reporting person was granted 2,546 restricted stock units: 1,846 vested immediately and 700 will vest on the one year anniversary of the grant date. F3 · derivative.expiration_date: On May 21, 2026, the reporting person was granted 2,546 restricted stock units: 1,846 vested immediately and 700 will vest on the one year anniversary of the grant date. Read SEC document |
| May 21, 2026 Filed May 27, 2026 00:12 UTC | RBB Bancorp RBB · Entity 5572 | Exercise / conversionRestricted Stock Units · Derivative | 700 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-018419 · rdgdoc.xml · derivative · entry 3 Pannu Geraldine · CIK 0001817209 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 700 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On May 21, 2025, the reporting person was granted 3,521 restricted stock units: 2,821 immediately vested and 700 vested on the one year anniversary of the grant date. F2 · derivative.expiration_date: On May 21, 2025, the reporting person was granted 3,521 restricted stock units: 2,821 immediately vested and 700 vested on the one year anniversary of the grant date. Read SEC document |
| May 21, 2026 Filed May 27, 2026 00:12 UTC | RBB Bancorp RBB · Entity 5572 | Exercise / conversionCommon Stock, No Par Value | 1,846 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-018419 · rdgdoc.xml · nonDerivative · entry 2 Pannu Geraldine · CIK 0001817209 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,267 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2026 Filed May 27, 2026 00:12 UTC | RBB Bancorp RBB · Entity 5572 | Exercise / conversionCommon Stock, No Par Value | 700 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-018419 · rdgdoc.xml · nonDerivative · entry 1 Pannu Geraldine · CIK 0001817209 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,421 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2026 Filed Apr 1, 2026 21:17 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 2,072 | $2.54 | $5,252.52 |
DisclosureSEC source: 0000897069-26-000752 · form4.xml · nonDerivative · entry 1 Pannu Geraldine · CIK 0001817209 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,188 Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 20:36 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantStock Options (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $0.20 | $0.00 |
DisclosureSEC source: 0000897069-25-001557 · form4.xml · derivative · entry 2 Pannu Geraldine · CIK 0001817209 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires not disclosed F2 · derivative.exercise_date: Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years. F2 · derivative.expiration_date: Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 20:36 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 100,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-25-001557 · form4.xml · derivative · entry 1 Pannu Geraldine · CIK 0001817209 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on October 1, 2026, and one-thirty-sixth each month thereafter until fully vested on October 1, 2028. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on October 1, 2026, and one-thirty-sixth each month thereafter until fully vested on October 1, 2028. Read SEC document |
| July 24, 2025 Filed Jul 28, 2025 20:17 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock · Derivative | 175,299 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-25-001207 · form4.xml · derivative · entry 1 Pannu Geraldine · CIK 0001817209 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 206,505 Underlying: Common Stock · 175,299 shares Expires not disclosed F1 · shares: Restricted stock granted under the Processa Pharmaceuticals, Inc. 2019 Omnibus Incentive Plan ("Omnibus Plan"), of which 125,999 shares are subject to stockholder approval of the revised Omnibus Plan. F2 · derivative.exercise_date: The restricted stock vest on the earlier of June 30, 2026 or the next annual meeting of stockholders, subject to certain distribution requirements. F2 · derivative.expiration_date: The restricted stock vest on the earlier of June 30, 2026 or the next annual meeting of stockholders, subject to certain distribution requirements. Read SEC document |
| May 21, 2025 Filed May 22, 2025 22:05 UTC | RBB Bancorp RBB · Entity 5572 | Exercise / conversionRestricted Stock Units · Derivative | 2,821 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-018216 · rdgdoc.xml · derivative · entry 2 Pannu Geraldine · CIK 0001817209 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 700 Underlying: Restricted Stock Units · 3,521 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These restricted stock units granted on 5/21/2025 vest in two installments:2,821 immediately vested on date of grant and 700 vest in one year from the date of grant F1 · derivative.expiration_date: There will be no expiration date once restricted stock units vest. Read SEC document |
| May 21, 2025 Filed May 22, 2025 22:05 UTC | RBB Bancorp RBB · Entity 5572 | Exercise / conversionCommon Stock, No Par Value | 2,821 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-018216 · rdgdoc.xml · nonDerivative · entry 1 Pannu Geraldine · CIK 0001817209 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,721 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2025 Filed May 16, 2025 17:37 UTC | RBB Bancorp RBB · Entity 5572 | Exercise / conversionRestricted Stock Units · Derivative | 700 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-017366 · rdgdoc.xml · derivative · entry 2 Pannu Geraldine · CIK 0001817209 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Restricted Stock Units · 700 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents 700 restricted stock units from a 5/15/2024 grant that vest one year from the date of grant. F1 · derivative.expiration_date: There will be no expiration date once restricted stock units vest. Read SEC document |
| May 15, 2025 Filed May 16, 2025 17:37 UTC | RBB Bancorp RBB · Entity 5572 | Exercise / conversionCommon Stock, No Par Value | 700 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-017366 · rdgdoc.xml · nonDerivative · entry 1 Pannu Geraldine · CIK 0001817209 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2024 Filed Sep 18, 2024 20:50 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock · Derivative | 31,206 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-24-001864 · form4.xml · derivative · entry 1 Pannu Geraldine · CIK 0001817209 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,206 Underlying: Common Stock · 31,206 shares Expires not disclosed F1 · derivative.exercise_date: The restricted stock vest on the earlier of June 28, 2025 or the next annual meeting of stockholders, subject to certain distribution requirements. F1 · derivative.expiration_date: The restricted stock vest on the earlier of June 28, 2025 or the next annual meeting of stockholders, subject to certain distribution requirements. Read SEC document |
| September 03, 2024 Filed Sep 18, 2025 20:22 UTC Amendment | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock · Derivative | 31,206 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-25-001500 · form4.xml · derivative · entry 1 Pannu Geraldine · CIK 0001817209 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,275 Underlying: Common Stock · 31,206 shares Expires not disclosed F1 · derivative.exercise_date: The restricted stock vest on the earlier of June 28, 2025 or the next annual meeting of stockholders, subject to certain distribution requirements. F1 · derivative.expiration_date: The restricted stock vest on the earlier of June 28, 2025 or the next annual meeting of stockholders, subject to certain distribution requirements. F2 · balance_after: Amending to correct the beneficially owned shares reported on the Form 4 filed September 18, 2024. Read SEC document |
| May 16, 2024 Filed May 17, 2024 23:02 UTC | RBB Bancorp RBB · Entity 5572 | Exercise / conversionRestricted Stock Units · Derivative | 800 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-017533 · rdgdoc.xml · derivative · entry 2 Pannu Geraldine · CIK 0001817209 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 700 Underlying: Restricted Stock Units · 1,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These restricted stock units vest in two installments: 800 immediately vested on the date of grant and 700 vest in one year from the date of grant. F1 · derivative.expiration_date: There will be no expiration date once restricted stock units vest. Read SEC document |
| May 16, 2024 Filed May 17, 2024 23:02 UTC | RBB Bancorp RBB · Entity 5572 | Exercise / conversionCommon Stock, No Par Value | 800 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-017533 · rdgdoc.xml · nonDerivative · entry 1 Pannu Geraldine · CIK 0001817209 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 18, 2024 Filed Jan 20, 2024 01:32 UTC | RBB Bancorp RBB · Entity 5572 | Exercise / conversionRestricted Stock Units · Derivative | 600 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-001773 · rdgdoc.xml · derivative · entry 2 Pannu Geraldine · CIK 0001817209 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Restricted Stock Units · 600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These restricted stock units vest in two installments: 800 at 01/18/2023 and 600 at 01/18/2024. F2 · derivative.expiration_date: There will be no expiration date once restricted stock units vest. Read SEC document |
| January 18, 2024 Filed Jan 20, 2024 01:32 UTC | RBB Bancorp RBB · Entity 5572 | Exercise / conversionCommon Stock, No Par Value | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-001773 · rdgdoc.xml · nonDerivative · entry 1 Pannu Geraldine · CIK 0001817209 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 10, 2023 Filed Oct 10, 2023 21:05 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantCommon Stock | 4,500 | $0.21 | $945.00 |
DisclosureSEC source: 0000897069-23-001446 · form4.xml · nonDerivative · entry 1 Pannu Geraldine · CIK 0001817209 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,613 Read SEC document |
| June 27, 2023 Filed Jul 24, 2023 22:26 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock · Derivative | 101,365 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-23-000998 · form4.xml · derivative · entry 3 Pannu Geraldine · CIK 0001817209 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,365 Underlying: Common Stock · 101,365 shares Expires not disclosed F2 · derivative.exercise_date: The Restricted Stock vests on the earliest of one year from date of grant or the next annual meeting of stockholders. F2 · derivative.expiration_date: The Restricted Stock vests on the earliest of one year from date of grant or the next annual meeting of stockholders. Read SEC document |
| June 27, 2023 Filed Jul 24, 2023 22:26 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionRestricted Stock · Derivative | 23,636 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-23-000998 · form4.xml · derivative · entry 2 Pannu Geraldine · CIK 0001817209 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,636 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Vesting of time-based restricted shares. F1 · derivative.expiration_date: Vesting of time-based restricted shares. Read SEC document |
| June 27, 2023 Filed Jul 24, 2023 22:26 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionCommon Stock | 23,636 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000897069-23-000998 · form4.xml · nonDerivative · entry 1 Pannu Geraldine · CIK 0001817209 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,113 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Vesting of time-based restricted shares. Read SEC document |
| January 18, 2023 Filed Jan 21, 2023 02:00 UTC | RBB Bancorp RBB · Entity 5572 | Exercise / conversionRestricted Stock Units · Derivative | 800 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-001512 · rdgdoc.xml · derivative · entry 2 Pannu Geraldine · CIK 0001817209 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600 Underlying: Restricted Stock Units · 1,400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These restricted stock units vest in two installments: 800 at 01/18/2023 and 600 at 01/18/2024. F2 · derivative.expiration_date: There will be no expiration date once restricted stock units vest. Read SEC document |
| January 18, 2023 Filed Jan 21, 2023 02:00 UTC | RBB Bancorp RBB · Entity 5572 | Exercise / conversionCommon Stock, No Par Value | 800 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-001512 · rdgdoc.xml · nonDerivative · entry 1 Pannu Geraldine · CIK 0001817209 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 01, 2023 Filed Jan 4, 2023 22:33 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock · Derivative | 30,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-000314 · doc1.xml · derivative · entry 2 Pannu Geraldine · CIK 0001817209 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires not disclosed F2 · derivative.exercise_date: The restricted stock vests on the earliest of one year from date of grant or the next annual meeting of stockholders. F2 · derivative.expiration_date: The restricted stock vests on the earliest of one year from date of grant or the next annual meeting of stockholders. Read SEC document |
| December 31, 2022 Filed Jan 4, 2023 22:33 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionCommon Stock | 18,208 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-23-000314 · doc1.xml · nonDerivative · entry 1 Pannu Geraldine · CIK 0001817209 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,477 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Vesting of time-based restricted shares. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 20:29 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionCommon Stock | 1,169 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-22-015309 · doc1.xml · nonDerivative · entry 1 Pannu Geraldine · CIK 0001817209 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,269 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Vesting of time-based restricted shares. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 21:56 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantCommon Stock | 4,393 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-22-008010 · doc1.xml · nonDerivative · entry 1 Pannu Geraldine · CIK 0001817209 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,100 F1 · price: Vesting of time-based restricted shares. Read SEC document |
| January 01, 2022 Filed Apr 20, 2022 01:21 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock · Derivative | 18,208 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-008685 · doc1.xml · derivative · entry 1 Pannu Geraldine · CIK 0001817209 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,377 Underlying: Common Stock · 18,208 shares Expires not disclosed F1 · derivative.exercise_date: Restricted stock units vest 100% on December 31, 2022. F1 · derivative.expiration_date: Restricted stock units vest 100% on December 31, 2022. Read SEC document |
| August 05, 2021 Filed Aug 9, 2021 20:46 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantCommon Stock | 1,169 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-21-014759 · doc1.xml · nonDerivative · entry 1 Pannu Geraldine · CIK 0001817209 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,707 F1 · price: Vesting of time-based restricted shares. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.